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A B S T R A C T
Phosphaturic mesenchymal tumor (PMT) is a rare neoplasm in which the tumor cells produce fibroblast growth
factor 23 (FGF23), leading to oncogenic osteomalacia and thus a distinct clinical presentation. However, the
pathologic findings of PMT are often non-specific and variable, especially in tumors occurring in the head and
neck. We present a case of a 66-year-old female who presented with osteomalacia-related symptoms and was
found to have a nasal cavity mass. Histopathologic examination was suggestive of PMT but certain characteristic
features were lacking, requiring confirmation of the diagnosis by chromogenic in situ hybridization (CISH) assay
for FGF23 mRNA. The patient's symptoms and laboratory abnormalities resolved upon resection of the tumor.
1. Introduction
Phosphaturic mesenchymal tumor (PMT) is a very rare neoplasm of
bone and soft tissue that is the most common cause of tumor induced
osteomalacia (TIO), a paraneoplastic syndrome caused by tumor cell
secretion of hormones that impair renal phosphate reuptake [1,2]. Fi-
broblast growth factor 23 (FGF23) is the most common of these hor-
mones termed “phosphatonins” [2]. In addition to laboratory abnorm-
alities such as hypophosphatemia and hyperphosphaturia, patients with
PMT usually present with symptoms and signs related to systemic bone
demineralization, such as bone pain, fractures, weakness and gait dis-
turbances [3]. A timely and accurate diagnosis is thus imperative for
initiating proper treatment in patients with suspected TIO [2].
The majority of PMTs occur in adults of a wide age range, and there
does not seem to be a gender predilection [1,3,4]. PMT most commonly
involves the bone or soft tissue of the extremities, while head and neck
sites represent only an estimated 5% of cases [3]. Of PMTs occurring in
the head and neck, extra-oral sites are more common than intra-oral
sites, and the sinonasal region is thought to be the most common site of
involvement, followed by the mandible, based on two series [3,5].
The typical microscopic morphology of PMT consists of cytologi-
cally bland spindle cells, osteoclast-like multinucleated giant cells,
stromal capillary vasculature, and chondromyxoid matrix with areas of
“grungy” basophilic calcification [1]. Microcystic change and mature
adipose tissue may also be seen [2]. For tumors displaying all of these
features, the diagnosis may be achieved without much difficulty,
especially in the context of characteristic clinical findings. However,
many cases will lack one or more of the above features, leading to a
diagnostic challenge [3]. Specifically, sinonasal tumors have been
noted to express disparate histologic features including increased cel-
lularity, minimal to no matrix, and prominent hemangiopericytoma-
like features [1]. In cases such as these, the detection of FGF23 ex-
pression can allow the pathologist to make a definitive diagnosis.
Various methods are currently available for detecting FGF23, including
immunohistochemistry, reverse transcription polymerase chain reac-
tion (RT-PCR) testing, and a newer method, chromogenic in situ hy-
bridization (CISH) for the detection of FGF23 mRNA in formalin-fixed
paraffin-embedded (FFPE) tissue sections [2]. We report a case of a
nasal cavity PMT with atypical histologic findings and a diagnosis
confirmed by CISH assay.
2. Clinical presentation
A 66-year-old female presented with a one-year history of pro-
gressive weakness in the legs and feet, which was later accompanied by
upper extremity pain and heaviness. She experienced difficulty standing
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up from a seated position, and she also had an abnormal gait and re-
quired the assistance of a walker. She later noted symptoms of nasal
obstruction, epistaxis, and headache. Additionally, she reported unin-
tentional weight loss of 20 pounds over a 6month period. Labs were
significant for a serum phosphate of 1.5 (reference range 2.4–4.5) mg/
dL. PET/CT revealed healing rib fractures and some focal increased
FDG uptake in the skull base. CT sinus and MRI skull base revealed a
3.2 cm ovoid mass in the posterior aspect of the left nasal cavity, with
abutment of the cribriform plate (Fig. 1). A biopsy of the mass showed a
vascular neoplasm of uncertain etiology. The patient was then referred
to our institution for further management.
The patient underwent complete endoscopic endonasal resection of
the mass with negative margins. Intraoperatively, the mass grossly
appeared as an encapsulated vascular mass attached to the septum,
middle turbinate, and anterior cranial base. The tumor also extended
intradurally into gyrus rectus and olfactory bulbs. Reconstruction was
accomplished with synthetic dural replacement and pedicled nasoseptal
flap.
3. Pathological findings
Histopathologic examination revealed bland oval to spindled cells
arranged in a peculiar configuration, in which the superficial sub-
epithelial space contained a highly cellular band-like zone of tumor
cells, and deep to this was a sharply demarcated, hypocellular area
containing hyaline to myxoid stroma devoid of calcification. A well-
developed vascular network was present throughout the tumor, ranging
from small capillaries to larger ectatic, often staghorn vessels. Areas of
microcystic change, hemosiderin deposition, and mature adipose tissue
were also identified (Fig. 2). There were no multinucleated giant cells
present. The tumor possessed histologically benign features, with
minimal cytologic atypia, low mitotic activity, and no necrosis. Im-
munohistochemical stains showed that the lesional cells were positive
for FLI-1 and weakly positive for ERG, while they were negative for
pancytokeratin, CD31, CD34, D2–40, STAT6, HMB-45, Melan-A, nu-
clear beta-catenin, smooth muscle actin and HHV-8 (Fig. 3). The Ki-67
proliferation index was 3%. The diagnosis of PMT was confirmed by
positive CISH for FGF23 mRNA (Fig. 4).
4. Clinical Follow-up
Following resection of the mass to negative margins, the patient
reported resolution of her bone pain and was able to ambulate without
a walker by her 3-week postoperative visit. Additionally, the patient's
phosphate normalized postoperatively to 4.2mg/dL within 9 weeks.
5. Discussion
PMT is an extremely rare neoplasm which may be under-recognized
by clinicians, surgeons or pathologists, especially when occurring at an
uncommon site such as in the head and neck. An additional challenge
for the pathologist is that PMTs occurring in the head and neck, spe-
cifically in the nose, often lack the distinctive calcified matrix that is
characteristic for PMT involving other anatomic sites. The case de-
scribed here also notably lacked the multinucleated giant cells which
are described as a common feature of PMT. These morphologic varia-
tions in an already rare entity may elude the pathologist; however close
attention to the patient's clinical presentation and laboratory findings is
crucial in including PMT in the differential diagnosis among its mor-
phologic mimics. In the current case, the differential included solitary
fibrous tumor (SFT), sinonasal glomangiopericytoma, and angiomyoli-
poma, while in other cases PMT may resemble giant cell tumor, os-
teosarcoma, or various chondroid lesions.
The unusual and relatively non-specific immunoprofile of PMT adds
to the diagnostic difficulty but is valuable in the exclusion of other
entities in the differential diagnosis. While a PMT may closely mimic
SFT or sinonasal glomangiopericytoma, as it did in the present case due
to the striking hemangiopericytoma-like vascular pattern, the im-
munohistochemical findings (negativity for CD34, STAT6, smooth
muscle actin and nuclear beta-catenin) do not support either of these
entities. In cases with adipose tissue co-existing with the prominent
vascular network, angiomyolipoma should be considered; however,
HMB-45 will be positive in angiomyolipoma and negative in PMT. In
addition to these pertinent negative stains, PMT has been shown to
consistently express ERG, CD56, SATB2 [1], FLI-1 [6] and SSTR2A [7].
The present case showed tumor cell expression of the endothelial
markers ERG and FLI-1, while the other common vascular markers
CD31, CD34 and D2–40 were negative.
Because the morphology and immunohistochemical findings may be
variable, detection of the FGF23 hormone secreted by PMT tumor cells
can help rule in or rule out a diagnostic suspicion of PMT.
Immunohistochemical testing of FGF23 offers wide availability and
preserves the morphology of the tissue, however the commercially
available antibody for FGF23 offers suboptimal specificity in diagnosing
PMT. Non-neoplastic cells, including osteoclasts and endothelial cells,
can show granular cytoplasmic staining with FGF23 im-
munohistochemistry [4]. SATB2 and SSTR2A stains mentioned above
may also show non-specific staining, within osteoblasts and endothelial
cells, respectively [1,7]. RT-PCR testing is another option for FGF23
identification and is highly sensitive; however, this method does not
permit tissue visualization and can be positive in other bone tumors due
to low-level FGF23 mRNA expression in non-neoplastic bone [2]. The
CISH assay for FGF23 mRNA developed at Mayo Clinic is highly sen-
sitive (96%) and specific (100%) for the diagnosis of PMT and allows
visualization of signals within FFPE tissue, proving to be immensely
useful for cases with variant histologic features or in biopsies with
limited material [2].
The consistent finding of TIO and FGF23 expression in PMT and the
majority of other osteomalacia-associated mesenchymal tumors lends
support that these entities represent morphologic variations of a single
Fig. 1. CT sinuses (coronal view). There is a mass filling the left nasal cavity
and abutting the cribriform plate.
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tumor type [4]. Recognition and complete resection is imperative, as
the TIO is cured upon removal of the mass. The majority of PMTs be-
have in a clinically benign fashion, however approximately 10% will
recur, and there are rare reports of metastatic tumors. Importantly,
cytologic features cannot always predict biologic behavior, as cytolo-
gically benign PMTs with metastatic spread have been documented [3].
6. Conclusion
PMT is a rare neoplasm but is the most common cause of TIO;
therefore, this diagnosis should be entertained in any patient presenting
with osteomalacia and a newly identified mass. The tumor may show
histologic heterogeneity leading to a broad differential diagnosis, but
confirmatory testing of FGF23 mRNA via CISH is available. While most
tumors show benign clinical behavior, recurrence and rarely metastasis
have been reported, warranting long-term clinical follow-up.
Fig. 2. Histologic findings. Hematoxylin and eosin (H&E)-stained sections show a dense band-like zone of hypercellularity just beneath the surface epithelium (A,
x20), transition to a hypocellular area with myxoid stroma (B, x200), prominent hemangiopericytoma-like areas with staghorn vessels (C, x100), microcystic change
(D, x200) and mature adipose tissue (E, x200). The lesional cells are oval to spindled with minimal cytologic atypia; hemosiderin deposition is also present (F, x400).
Fig. 3. Immunohistochemical findings. ERG shows strong staining in the endothelial lining of the vessels and weaker staining in the tumor cells (A, x400). FLI-1
shows equally strong staining in the tumor cells and vascular lining cells (B, x400).
Fig. 4. CISH for FGF23 mRNA. The tumor cells are strongly positive.
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